- Gilead Sciences
Gilead Sciences, a biopharma company, achieves bold ambitions to help make the world a healthier place, leading in HIV, liver disease, cancer inflammation
- Careers at Gilead Sciences
Gilead, a global biopharma co pursuing innovation in virology, oncology and inflammation, offers a variety of career opportunities in an inclusive workplace where all can make an impact
- Gilead Sciences: Company
Learn about the biopharmaceutical company Gilead Sciences, including mission, vision, values, history, impact, leadership, therapeutic areas and other information
- Medicines - Gilead Sciences
The content in this page is intended only for residents of the United States The medicines displayed herein may have different labeling in different countries
- U. S. FDA Accepts Gileads New Drug Applications for Twice Yearly . . .
FOSTER CITY, Calif --(BUSINESS WIRE)-- Gilead Sciences, Inc (Nasdaq: GILD) today announced that the U S Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) submissions for lenacapavir—the company’s twice-yearly injectable HIV-1 capsid inhibitor—for the prevention of HIV as pre-exposure prophylaxis (PrEP) The FDA will review the applications under priority
- Gilead Sciences, Inc. - Investor Relations
At Gilead, we’re committed to creating a healthier world for everyone – no matter the challenges ahead of us For more than 30 years, we’ve pursued the impossible, chased it down, tackled it for answers and surrounded it for a way in
- Virology, Inflammation, Oncology Pipeline | Gilead
Through science and innovative partnerships, Gilead expands research and development programs in virology, oncology, inflammation Learn about our pipeline
- Gilead Sciences Therapeutic Areas: Virology, Oncology Inflammation
We continue to set bold ambitions in our pursuit of a healthier world for all people We’re building on our legacy in virology by helping to end the HIV epidemic for everyone, everywhere, including through the development of long-acting options for PrEP (pre-exposure prophylaxis), by aiming to eliminate hepatitis C as a public health problem, and preparing for future infectious diseases
|